| Name | Title | Contact Details |
|---|
Tobira Therapeutics is a clinical-stage biopharmaceutical company developing cenicriviroc (CVC), an oral potent dual inhibitor of chemokine receptors CCR2 and CCR5. Tobira is initiating a Phase 2 clinical trial of cenicriviroc for the treatment of Nonalcoholic Steatohepatitis (NASH), a leading cause of cirrhosis and liver transplant. The company has also completed a Phase 2b clinical trial of cenicriviroc in 143 HIV-infected subjects, and the compound is positioned for Phase 3 studies as a novel, once daily, fixed-dose cenicriviroc/lamivudine backbone as part of combination HIV therapy. Tobira is backed by a syndicate of leading life science investors including Domain Associates, Frazier Healthcare Ventures, Montreux Equity Partners, Novo Ventures and Canaan Partners.
Critical Outcome Technologies Inc. is a London, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Advancing orthobiologics to enhance the body’s ability to heal. Bioventus’ products are known for their safety, innovation, and effectiveness.
Vascular Vision Pharmaceutical Co is a Wynantskill, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Advance with TriRx. Your contract development & manufacturing organization focused on non-sterile & sterile products, animal health injectables & packaging.